Excalipoint Therapeutics, Inc.

Excalipoint Therapeutics, Inc. is a biotechnology company based in Shanghai, China, focused on developing innovative solutions for health challenges through advanced biomolecular technologies. Founded in 2026, Excalipoint Therapeutics, Inc. specializes in biotechnology aimed at developing therapeutics for cancer and autoimmune diseases.

The company has conducted a total of 2 deals. Its latest funding round was a Seed round in February 2026, raising USD 27. 7 mn from investors including Centurium Capital and MPC, among others. The company operates from its headquarters in Shanghai, China.

Excalipoint Therapeutics, Inc. specializes in biotechnological products aimed at addressing specific health and wellness challenges. The company’s core offerings include a variety of innovative biological solutions designed for clinical applications, including diagnostics and therapeutic treatments. These products are engineered to enhance patient outcomes through advanced biomolecular technologies, primarily serving healthcare providers and institutions.

The company's customer base extends across Asia and Europe, targeting hospitals, research laboratories, and pharmaceutical companies seeking effective solutions. The revenue structure of Excalipoint Therapeutics, Inc. is based on direct sales to healthcare providers and institutions, characterized by B2B transactions that focus on delivering tailored solutions. The company collaborates with distributors and wholesalers to expand its reach in both domestic and international markets.

Revenue is primarily generated from flagship products available under specific pricing models that reflect their advanced technological attributes and clinical value, often involving agreements for regular replenishment orders or longer-term contracts to ensure a stable income stream. In February 2026, Excalipoint Therapeutics, Inc. raised USD 27. 7 mn in a Seed funding round to advance its proprietary technology platforms and develop its pipeline of T-cell engager programs targeting cancer and autoimmune diseases.

The company plans to launch new products aimed at these health challenges and expand its market reach into additional geographic regions by the end of 2026. The funding will support the advancement of these initiatives and strengthen its position in the biotechnology sector.